Orlando Giuseppina, Scerrino Gregorio, Corigliano Alessandro, Vitale Irene, Tutino Roberta, Radellini Stefano, Cupido Francesco, Graceffa Giuseppa, Cocorullo Gianfranco, Salamone Giuseppe, Melfa Giuseppina
Department of Surgical Oncology and Oral Sciences, Unit of General and Emergency Surgery, University of Palermo, Palermo, Italy.
Section of Endocrinology - Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.
Front Oncol. 2022 Mar 23;12:859461. doi: 10.3389/fonc.2022.859461. eCollection 2022.
Active surveillance is considered a viable option for papillary thyroid microcarcinoma. Since the last decade of the 20th century, this method has spread from Japan to other countries, but has not yet been fully accepted and validated by the major Western Scientific Societies. In 2016, a systematic review on the results of active surveillance was published, based on two articles that showed encouraging results. Other reviews published subsequently, were mainly based on articles from the Far East. The aim of this review is to assess the most recent results published from 2017 to 2020 on this subject.
A systematic literature search was performed on MEDLINE PUBMED, Web of Science, and Scopus according to PRISMA criteria. The MESH terms "papillary thyroid microcarcinoma" and "active surveillance" were adopted. Tumor progression, secondary localizations, and quality of life were the main benchmarks.
Nine studies met the inclusion criteria. The increase in volume ranged from 2.7% and 23.2%; the occurrence of lymph node metastases from 1.3% to 29%; QoL was improved in both articles that addressed this topic. The level of evidence is considered low due to the retrospective and uncontrolled nature of most of the studies included in the review.
The evidence from the literature currently available on AS falls into two strands: a robust data set from the Japanese experience, and an initial experience from Western countries, whose data are still limited but which show a lack of substantial alerts against this practice. Further data is useful to validate the spread of Active Surveillance.
主动监测被认为是甲状腺微小乳头状癌的一种可行选择。自20世纪最后十年以来,这种方法已从日本传播到其他国家,但尚未得到西方主要科学协会的充分认可和验证。2016年,基于两篇显示出令人鼓舞结果的文章,发表了一篇关于主动监测结果的系统评价。随后发表的其他综述主要基于来自远东地区的文章。本综述的目的是评估2017年至2020年发表的关于该主题的最新结果。
根据PRISMA标准,在MEDLINE、PUBMED、科学网和Scopus上进行了系统的文献检索。采用了医学主题词“甲状腺微小乳头状癌”和“主动监测”。肿瘤进展、继发定位和生活质量是主要的衡量标准。
九项研究符合纳入标准。体积增加范围为2.7%至23.2%;淋巴结转移发生率为1.3%至29%;在涉及该主题的两篇文章中,生活质量均得到改善。由于综述中纳入的大多数研究具有回顾性和非对照性,证据水平被认为较低。
目前关于主动监测的文献证据分为两类:来自日本经验的强大数据集,以及来自西方国家的初步经验,其数据仍然有限,但并未显示出对此做法的重大警示。进一步的数据对于验证主动监测的推广很有用。